Innovent Biologics Stock Short Ratio
| IVBXF Stock | USD 4.85 0.24 4.72% |
Innovent Biologics fundamentals help investors to digest information that contributes to Innovent Biologics' financial success or failures. It also enables traders to predict the movement of Innovent Pink Sheet. The fundamental analysis module provides a way to measure Innovent Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Innovent Biologics pink sheet.
Innovent |
Innovent Biologics Company Short Ratio Analysis
Innovent Biologics' Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
The higher the Short Ratio, the longer it would take to buy back the borrowed shares. In theory, the more short positions are currently outstanding, the faster it will be to cover shorted positions.
| Competition |
Based on the latest financial disclosure, Innovent Biologics has a Short Ratio of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The short ratio for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
Innovent Fundamentals
| Return On Equity | -0.29 | |||
| Return On Asset | -0.14 | |||
| Profit Margin | (0.68) % | |||
| Operating Margin | (0.78) % | |||
| Current Valuation | 5.13 B | |||
| Shares Outstanding | 1.53 B | |||
| Shares Owned By Insiders | 7.15 % | |||
| Shares Owned By Institutions | 44.34 % | |||
| Price To Book | 4.22 X | |||
| Price To Sales | 1.39 X | |||
| Revenue | 4.27 B | |||
| Gross Profit | 2.98 B | |||
| EBITDA | (2.99 B) | |||
| Net Income | (3.14 B) | |||
| Cash And Equivalents | 8.32 B | |||
| Cash Per Share | 5.67 X | |||
| Total Debt | 2.02 B | |||
| Debt To Equity | 0.29 % | |||
| Current Ratio | 3.21 X | |||
| Book Value Per Share | 6.54 X | |||
| Cash Flow From Operations | (2.02 B) | |||
| Earnings Per Share | (0.32) X | |||
| Number Of Employees | 5.54 K | |||
| Beta | 0.16 | |||
| Market Capitalization | 8.37 B | |||
| Total Asset | 16.24 B | |||
| Z Score | 2.4 | |||
| Net Asset | 16.24 B |
About Innovent Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Innovent Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Innovent Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Innovent Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Innovent Pink Sheet
Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.